Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maureen McMahon

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Expert Opinion on Investigational Drugs|July 12, 2008
Inflammatory lipids as a target for therapy in the rheumatic diseasesMaureen McMahon, Ernest Brahn
Nursing Management|January 25, 2003
Achieve ED restraint reductionMaureen McMahon, Linda Fisher
Dimensions of Critical Care Nursing : DCCN|September 26, 2003
Achieve emergency department restraint reductionMaureen McMahon, Linda Fisher
Nature Reviews. Rheumatology|July 1, 2016
Autoimmunity: Do IgM antibodies protect against atherosclerosis in SLE?Maureen McMahon, Brian Skaggs
Rheumatic Diseases Clinics of North America|July 19, 2014
Pathogenesis and treatment of atherosclerosis in lupusMaureen McMahon, Brian Skaggs
The Journal of Rheumatology|August 13, 2003
The risk of contralateral total knee arthroplasty after knee replacement for osteoarthritisMaureen McMahon, Joel A Block
Current Opinion in Immunology|December 18, 2007
Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the associationMaureen McMahon, Bevra H Hahn
The Journal of Rheumatology|April 1, 2026
Rethinking Cardiovascular Screening in Systemic Lupus ErythematosusMaureen McMahon, Brian J Skaggs
Lupus Science & Medicine|April 2, 2020
Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progressionEmily Liang, Mihaela Taylor, Maureen McMahon
Arthritis and Rheumatism|April 13, 2004
Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?Dinesh Khanna, Maureen McMahon, Daniel E Furst
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Expert Opinion on Investigational Drugs|July 12, 2008
Inflammatory lipids as a target for therapy in the rheumatic diseasesMaureen McMahon, Ernest Brahn
Nursing Management|January 25, 2003
Achieve ED restraint reductionMaureen McMahon, Linda Fisher
Dimensions of Critical Care Nursing : DCCN|September 26, 2003
Achieve emergency department restraint reductionMaureen McMahon, Linda Fisher
Nature Reviews. Rheumatology|July 1, 2016
Autoimmunity: Do IgM antibodies protect against atherosclerosis in SLE?Maureen McMahon, Brian Skaggs
Rheumatic Diseases Clinics of North America|July 19, 2014
Pathogenesis and treatment of atherosclerosis in lupusMaureen McMahon, Brian Skaggs
The Journal of Rheumatology|August 13, 2003
The risk of contralateral total knee arthroplasty after knee replacement for osteoarthritisMaureen McMahon, Joel A Block
Current Opinion in Immunology|December 18, 2007
Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the associationMaureen McMahon, Bevra H Hahn
The Journal of Rheumatology|April 1, 2026
Rethinking Cardiovascular Screening in Systemic Lupus ErythematosusMaureen McMahon, Brian J Skaggs
Lupus Science & Medicine|April 2, 2020
Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progressionEmily Liang, Mihaela Taylor, Maureen McMahon
Arthritis and Rheumatism|April 13, 2004
Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?Dinesh Khanna, Maureen McMahon, Daniel E Furst
Pageof 6